TELA Bio TELA 深 沪
等待开盘 07-29 09:30:00 美东时间
1.90
-0.020
-1.04%
华盛通- 最 高1.97
- 今 开1.93
- 成交量 5.89万股
- 最 低 1.90
- 昨 收 1.92
- 总市值 7515.45万
- 52周最高 4.30
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 0.8645
- 委 比 85.24%
- 总股本 3955.50万
- 历史最高 23.545
- 量 比 1.29
- 振 幅 3.65%
- 历史最低 0.8645
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
TELA Bio, Inc. will participate in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:00 am ET. The company's management will present, and interested parties can access the live or archived webcast via ir.telabio.com. TELA Bio focuses on providing innovative soft-tissue reconstruction solutions. For more information, contact Louisa Smith at ir@telabio.com.
07-23 20:03
TELA Bio to Announce Second Quarter 2025 Financial Results
TELA Bio, Inc. will release its Q2 2025 financial results on August 11, 2025, followed by a conference call and webcast at 4:30 p.m. ET. Interested investors must register in advance. TELA Bio focuses on innovative soft-tissue reconstruction solutions, emphasizing patient anatomy preservation and natural healing. The company is committed to providing effective and economical solutions for surgeons. This press release includes forward-looking stat...
07-21 20:03
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Inc. granted an inducement compensation package including stock options for 75,000 shares and restricted stock units for 30,000 shares to Jim Hagen, Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025. The stock options have an exercise price of $1.42 per share and vest over four years, with the restricted stock units also vesting over four years, contingent on continued employment.
06-06 20:05
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
TELA Bio, Inc. announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, a reinforced tissue matrix designed for laparoscopic and robotic-assisted inguinal hernia repair. Following its successful U.S. launch in 2024 with over $1 million in sales, OviTex Inguinal is now available in Europe in two configurations: three- or four-layer anatomically shaped devices for laparoscopic and robotic procedures. The product builds on the OviT...
06-03 20:05
TELA Bio Appoints Jeffrey Blizard as President
TELA Bio appoints Jeffrey Blizard as President to drive growth. Blizard, with extensive experience in medical technology, joins from Abiomed. CEO Antony Koblish emphasizes Jeff's leadership and track record in scaling businesses. Blizard plans to accelerate execution and strengthen customer relationships. TELA Bio focuses on innovative soft-tissue reconstruction solutions.
06-02 12:30
TELA Bio Affirms FY2025 Sales Guidance of $85.00M-$88.00M vs $85.54M Est
TELA Bio (NASDAQ:TELA) affirms FY2025 sales outlook from $85.00 million-$88.00 million to $85.00 million-$88.00 million vs $85.54 million estimate.
05-09 04:29
TELA Bio Q1 EPS $(0.25) Misses $(0.23) Estimate, Sales $18.52M Beat $17.36M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 53.7 percent increase over losses of $(0.54) per share from the same
05-09 04:28
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
Shuttle Pharmaceuticals Has Been Granted A European Patent Titled "DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION (FOR TREATMENT OF CANCERS, NEUROLOGICAL DISORDERS, & IMMUNOLOGICAL DISORDERS)"
https://data.epo.org/publication-server/publications/pdf?path=2025/19/DOC/EPNWB1/EP21191547NWB1/EP21191547NWB1.pdf
05-07 20:19
美股大行评级 | 高盛：上调Adaptive Biotechnologies评级至"买入"，目标价从8美元升至9美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1110125309827231744.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Amprius Technologies(AMPX)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 韦德布什：维持Monte Rosa Therapeutics(GLUE)"跑
03-24 07:31
